KR880009653A - 혈액중 요산농도를 감소시키는데 유용한 치료제 - Google Patents

혈액중 요산농도를 감소시키는데 유용한 치료제 Download PDF

Info

Publication number
KR880009653A
KR880009653A KR1019880002083A KR880002083A KR880009653A KR 880009653 A KR880009653 A KR 880009653A KR 1019880002083 A KR1019880002083 A KR 1019880002083A KR 880002083 A KR880002083 A KR 880002083A KR 880009653 A KR880009653 A KR 880009653A
Authority
KR
South Korea
Prior art keywords
salts
pharmaceutically acceptable
acid
acceptable salt
fluorobenzyl
Prior art date
Application number
KR1019880002083A
Other languages
English (en)
Inventor
트리붸 씨럼 페르
Original Assignee
원본미기재
임페리얼 케미칼 인더스트리스 아메리카스 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 임페리얼 케미칼 인더스트리스 아메리카스 인코오포레이티드 filed Critical 원본미기재
Publication of KR880009653A publication Critical patent/KR880009653A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
  • Semiconductor Lasers (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음.

Description

혈액중 요산농도를 감소시키는데 유용한 치료제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 남성 비인슐린 의존 당뇨병 환자에 포널레스테트를 경구투여시의 혈청 요산농도의 효과를 나타낸 그래프.

Claims (8)

  1. 3-(4-브로모-2-플루오로벤질)-4-옥소-3H-프탈라진-1-일아세트산 또는 이것의 약학적 허용염을 포함하는 것을 특징으로 하는 혈액중의 요산농도를 감소시키는데 사용되는 치료제.
  2. 제1항에 있어서, 상기 산의 약학적 허용염은 알칼리 금속 및 알칼리토금속염류, 알루미늄 및 암모늄염, 및 트리에탄올 아민을 지닌 염과 같은 약학적 허용 양이온을 제공하는 유기염기를 지닌 염에서 선택되는 것을 특징으로 하는 치료제.
  3. 온형동물중의 혈액중 요산 농도를 감소시키는데 사용하기 위한 신규 약제를 제조하는데 3-(4-브로모-2-플루오로벤질)-4-옥소-3H-플탈라진-1-일아세트산을 이용하는 방법.
  4. 제3항에 있어서, 상기산의 약학적 허용염은 알칼리 금속 및 알칼리토금속염류, 알루미늄 및 암모늄염, 및 트리에탄올아민을 지닌 염과 같은 약학적 허용 양이온을 제공하는 유기 염기를 지닌 염에서 선택되는 것을 특징으로 하는 용도의 발명.
  5. 고요산혈증에 효과적인 함량으로 3-(4-브로모-2-플루오로벤질)-4-옥소-3H-프탈진-1-일아세트산 또는 이것의 약학적 허용염을 동물에 투여하는 것을 포함하는 이러한 치료를 필요로 하는 온혈동물에 고요산혈증 효과를 내는 방법.
  6. 제5항에 있어서, 상기 산의 약학적 허용염은 알칼리금속 및 알칼리토금속염류, 알루미늄 및 암모늄염, 및 트리에탄올아민을 지닌 염과 같은 약학적 허용염을 제공하는 유기염기를 지닌 염에서 선택되는 것을 특징으로 하는 방법.
  7. 고요산혈증 치료제로서의 3-(4-브로모-2-플루오로벤질)-4-옥소-3H-프탈라진-1-일아세트산 또는 이것의 약학적허용염.
  8. 고요산혈증 치료제로서의 나트륨 또는 칼륨 3-(4-브로모-2-플루오로벤질)-4-옥소-3H-프탈라진-1-일아세테이트.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880002083A 1987-02-26 1988-02-26 혈액중 요산농도를 감소시키는데 유용한 치료제 KR880009653A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8704569 1987-02-26
GB878704569A GB8704569D0 (en) 1987-02-26 1987-02-26 Therapeutic agent

Publications (1)

Publication Number Publication Date
KR880009653A true KR880009653A (ko) 1988-10-04

Family

ID=10613007

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880002083A KR880009653A (ko) 1987-02-26 1988-02-26 혈액중 요산농도를 감소시키는데 유용한 치료제

Country Status (12)

Country Link
US (1) US4895843A (ko)
EP (1) EP0296695B1 (ko)
JP (1) JPH01216931A (ko)
KR (1) KR880009653A (ko)
AT (1) ATE81005T1 (ko)
DE (1) DE3874978T2 (ko)
DK (1) DK169304B1 (ko)
ES (1) ES2052701T3 (ko)
GB (2) GB8704569D0 (ko)
GR (1) GR3006256T3 (ko)
HU (1) HU197845B (ko)
IE (1) IE61934B1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064830A (en) * 1990-08-02 1991-11-12 Pfizer Inc. Lowering of blood uric acid levels
US8273746B2 (en) 2007-03-23 2012-09-25 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture

Also Published As

Publication number Publication date
EP0296695B1 (en) 1992-09-30
DK99488D0 (da) 1988-02-25
ATE81005T1 (de) 1992-10-15
GR3006256T3 (ko) 1993-06-21
IE880515L (en) 1988-08-26
JPH01216931A (ja) 1989-08-30
HU197845B (en) 1989-06-28
EP0296695A2 (en) 1988-12-28
GB8704569D0 (en) 1987-04-01
HUT46213A (en) 1988-10-28
ES2052701T3 (es) 1994-07-16
US4895843A (en) 1990-01-23
DK99488A (da) 1988-08-27
DE3874978T2 (de) 1993-02-18
EP0296695A3 (en) 1990-07-18
IE61934B1 (en) 1994-11-30
DE3874978D1 (de) 1992-11-05
GB2201343A (en) 1988-09-01
GB2201343B (en) 1990-11-14
GB8803763D0 (en) 1988-03-16
DK169304B1 (da) 1994-10-10

Similar Documents

Publication Publication Date Title
ATE113213T1 (de) Gerät zur vorläufigen reperfusionsbehandlung von herzanfallsymptomen.
KR950700060A (ko) 운동 뉴우런 질병의 치료에 유용한 약품을 얻기 위한 2-아미노-6-트리플루오로메톡시 벤조티아졸(리루졸)의 사용(Application of 2-amino 6-trifluoromethoxy benzothiazole(riluzole) for obtaining a drug useful in the treatment of motor neuron diseases)
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
SE8406538D0 (sv) Novel derivatives of purine
IE41374B1 (en) A composition for treating schizophrenia
DE69116380T2 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
YU46559B (sh) Postupak za dobivanje novih derivata difenilpropilamina
SE7902742L (sv) Disubstituerade 3-cefem-4-karboxylsyraderivat samt forfarande for framstellning derav
SE8105561L (sv) Anvendning av pyridoxin-alfa-ketoglutarat vid profylax av hypermjolksyraemi
KR970025615A (ko) 암 전이 억제제
KR950703527A (ko) 프로스타글란딘 유도체
BRPI0514891A (pt) composição contendo derivados de prostaglandina e uso da referida composição
KR880009653A (ko) 혈액중 요산농도를 감소시키는데 유용한 치료제
KR890006621A (ko) 항불안제
KR890012942A (ko) 5-치환된 오르니틴 유도체
KR890008136A (ko) 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체
KR880004810A (ko) 소화성 궤양 치료제
KR880009656A (ko) 국소 치근막 질환의 치료 또는 예방법
KR950032191A (ko) 사이클로헥산 유도체, 이의 제조방법 및 질병을 치료하기 위한 화합물의 용도
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
KR900701273A (ko) 진토성 에르골린 유도체
KR880009644A (ko) 궤양성 대장질환 치료용 약한 조성물
KR900017599A (ko) 종양 치료용 약학 조성물
EA200700968A1 (ru) Фармацевтическая композиция для лечения сахарного диабета 2 типа

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application